No Data
Applied Therapeutics CRL a 'Major Setback,' Says William Blair
Applied Therapeutics Downgraded to Sector Perform From Outperform at RBC
Applied Therapeutics Stock Plummets 73%. The FDA Delivers This Crushing Blow
Applied Therapeutics Price Target Cut to $8.00/Share From $13.00 by Citigroup
Applied Therapeutics Is Maintained at Buy by Citigroup
Applied Therapeutics Price Target Raised to $13.00/Share From $11.00 by Citigroup
105642463xu : $KULR Technology (KULR.US)$
Jaguar8 OP 105642463xu : Yup its on my watchlist
Rosscco : Thanks for the tip !
Adria87 : Thank You for the tip
baqklin : not a good play if 66% is moved to dark pool?
View more comments...